Clinical Trials Update: June 20, 2005
Brain Tumor (Pediatric) Lymphomas Crohn's Disease
(HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch:
Brain Tumor (Pediatric)
The purpose of this study is to see how well patients with non-germinomatous germ cell tumor (NGGCT) respond to the anti-cancer drugs (chemotherapy) used in the first part of this study called induction. These drugs are carboplatin, etoposide (VP-16), and ifosfamide. Looking for patients 3 to 24 years old who have been diagnosed with a type of brain cancer called non-germinomatous germ cell tumor. Research site located in Cincinnati, Ohio.
A Phase I, multi-center, repeat-dose study of oral forodesine hydrochloride in patients with refractory cutaneous t-cell lymphoma. Patients will receive a once-daily oral dose of forodesine hydrochloride for 28 days. At the end of the 28 day period, responsive patients may enter a long-term period to receive the drug and will be followed for safety and efficacy. Participants must be men or non-pregnant, non-lactating women at least 18 years of age, with previously treated, refractory CTCL. Research sites located in Ohio, Florida and Massachusetts.
The purpose of this phase 3 study is to evaluate the effectiveness of sargramostim in patients with active Crohn's disease. The study drug is a man-made form of the colony stimulating factor, GM-CSF. GMV-CSF is a small protein molecule that helps fight inflammation and stimulate components of your immune system (such as white blood cells). The ideal patient for this study is at least 18 years old with active Crohn's disease. The study will involve approximately 330 patients at 100 sites nationwide. Research sites located throughout the United States.
Copyright 2005 CenterWatch. All rights reserved.